National AMR action plans and immunization programmes: key policy priorities in the fight against AMR
A multi-faceted strategy is needed to successfully manage AMR, a silent pandemic that threatens our ability to treat common infections. Vaccines are critical in helping to combat the growing crisis. The upcoming revision of the Council Recommendations on AMR provides a great opportunity to update European policy.
Anti-microbial resistance (AMR) is a silent pandemic that is estimated to cause approximately 33,000 deaths each year in Europe. The emergence and spread of drug-resistant pathogens that have acquired new resistance mechanisms, leading to antimicrobial resistance, continues to threaten our ability to treat common infections.
A multi-faceted strategy is needed to successfully manage AMR. An abundance of evidence demonstrates that vaccines are critical in helping to combat the growing AMR crisis, by helping prevent both bacterial and viral diseases, as well as commonly-acquired bacterial infections, including hospital-acquired infections (HAIs).
The upcoming revision of the Council Recommendations on AMR provides a great opportunity to update European policy recommendations and incorporate best practice based on lessons learnt over the last two decades.
In this context Lif in collaboration with Vaccines Europe organise a webinar to take stock of the situation in Europe, share best practice and provide input to the upcoming Council negotiations. The target audience is policy makers and stakeholders in Brussels and the EU Member States.
Speakers
John Paget (NIVEL), Sibilia Quilici (Vaccines Europe) and Jaime Jesús Pérez Martín (ES/Murcia)
Moderator: Bengt Mattson, Lif